Literature DB >> 19199953

Features and strategies of ENU mouse mutagenesis.

Dian Soewarto1, Matthias Klaften, Isabel Rubio-Aliaga.   

Abstract

Aim of this review is to demonstrate the relevance of animal models created by ENU mutagenesis for the pharmaceutical community to understand diseases and the modulation of disease status by pharmaceutical compounds. We give an overview of what ENU mutagenesis in mice implies and introduce the main research centers running ENU mutagenesis projects. The different strategies of ENU mutagenesis screens are explained as well as the latest advances in mapping and mutation detection strategies, which until recently have been the main limiting step in forward genetics/phenotype-driven approaches. ENU mutagenesis in mice has shown its power by providing animal models for human monogenic diseases. Moreover, the development of modifier and sensitized screens extended this resource to models for multigenic diseases and thereby opened the perspective to understand the modulation of disease states. Finally, we provide information about the accessibility and availability of these models for academic research.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19199953     DOI: 10.2174/138920109787315079

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  6 in total

1.  The Sweet Pee model for Sglt2 mutation.

Authors:  Joseph P Ly; Tuncer Onay; Karen Sison; Gavasker Sivaskandarajah; Venkata Sabbisetti; Lingli Li; Joseph V Bonventre; Ann Flenniken; Neal Paragas; Jon M Barasch; S Lee Adamson; Lucy Osborne; Janet Rossant; Jurgen Schnermann; Susan E Quaggin
Journal:  J Am Soc Nephrol       Date:  2011-01       Impact factor: 10.121

2.  Identification of Arhgef12 and Prkci as genetic modifiers of retinal dysplasia in the Crb1rd8 mouse model.

Authors:  Sonia M Weatherly; Gayle B Collin; Jeremy R Charette; Lisa Stone; Nattaya Damkham; Lillian F Hyde; James G Peterson; Wanda Hicks; Gregory W Carter; Jürgen K Naggert; Mark P Krebs; Patsy M Nishina
Journal:  PLoS Genet       Date:  2022-06-08       Impact factor: 6.020

Review 3.  Towards better mouse models: enhanced genotypes, systemic phenotyping and envirotype modelling.

Authors:  Johannes Beckers; Wolfgang Wurst; Martin Hrabé de Angelis
Journal:  Nat Rev Genet       Date:  2009-06       Impact factor: 53.242

4.  New mouse models for metabolic bone diseases generated by genome-wide ENU mutagenesis.

Authors:  Sibylle Sabrautzki; Isabel Rubio-Aliaga; Wolfgang Hans; Helmut Fuchs; Birgit Rathkolb; Julia Calzada-Wack; Christian M Cohrs; Matthias Klaften; Hartwig Seedorf; Sebastian Eck; Ana Benet-Pagès; Jack Favor; Irene Esposito; Tim M Strom; Eckhard Wolf; Bettina Lorenz-Depiereux; Martin Hrabě de Angelis
Journal:  Mamm Genome       Date:  2012-04-21       Impact factor: 2.957

5.  Exposure to N-ethyl-N-nitrosourea in adult mice alters structural and functional integrity of neurogenic sites.

Authors:  Vivian Capilla-Gonzalez; Sara Gil-Perotin; Antonio Ferragud; Luis Bonet-Ponce; Juan Jose Canales; Jose Manuel Garcia-Verdugo
Journal:  PLoS One       Date:  2012-01-04       Impact factor: 3.240

6.  Defective immuno- and thymoproteasome assembly causes severe immunodeficiency.

Authors:  Irina Treise; Eva M Huber; Tanja Klein-Rodewald; Wolfgang Heinemeyer; Simon A Grassmann; Michael Basler; Thure Adler; Birgit Rathkolb; Laura Helming; Christian Andres; Matthias Klaften; Christina Landbrecht; Thomas Wieland; Tim M Strom; Kathy D McCoy; Andrew J Macpherson; Eckhard Wolf; Marcus Groettrup; Markus Ollert; Frauke Neff; Valerie Gailus-Durner; Helmut Fuchs; Martin Hrabě de Angelis; Michael Groll; Dirk H Busch
Journal:  Sci Rep       Date:  2018-04-13       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.